# Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

> **NCT02555215** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 20 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** dimethyl fumarate

## Key facts

- **NCT ID:** NCT02555215
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-22
- **Primary completion:** 2018-09-24
- **Final completion:** 2018-09-24
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02555215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02555215, "Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02555215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*